Open AccessCorrelating blood-based DNA methylation markers and prostate cancer risk in African-American men
Author(s) -
Emmanuel Moses-Fynn,
Wei Tang,
Desta Beyene,
Victor Apprey,
Robert L. Copeland,
Yasmine Kanaan,
Bernard Kwabi-Addo
Publication year - 2018
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0203322
Subject(s) - dna methylation , methylation , epigenetics , prostate cancer , cancer , gene , promoter , biology , microbiology and biotechnology , medicine , oncology , genetics , gene expression
The objective of this work was to investigate the clinical significance of promoter gene DNA methylation changes in whole blood from African-American (AA) men with prostate cancer (PCa). We used high throughput pyrosequencing analysis to quantify percentage DNA methylation levels in a panel of 8 genes ( RARβ 2, TIMP 3, SPARC , CDH 13, HIN 1, LINE 1, CYB 5 R 2 and DRD 2) in blood DNA obtained from PCa and non-cancerous controls cases. Correlations of methylation status and various clinicopathological features were evaluated. Six genes tested achieved significant difference in DNA methylation levels between the PCa compared to control cases (P < 0.05). The TIMP 3 loci demonstrated significant correlation of DNA methylation with age for all cases analyzed (p < 0.05). We observed an inverse correlation between CDH 13 methylation (p = 0.045; r = -0.21) and serum vitamin D level whereas TIMP 3 methylation (p = 0.021; r = -0.24) and DRD 2 methylation (p = 0.056; r = -0.201) showed inverse correlation with supplementary vitamin D in the cancer cases. We also observed a direct correlation between methylation of RARβ 2 (p = 0.0036; r = 0.293) and SPARC (p = 0.0134; r = 0.20) loci with PSA level in the controls but not the cancer cases. In addition, alcohol cases significantly correlated with higher RARβ 2 methylation (p = 0.0314) in comparison with non-alcohol cases. Furthermore, we observed an inverse correlation of DRD 2 methylation (p = 0.0349; r = -0.343) and Gleason score. Our data suggests that promoter methylation occurred more frequently in the blood of AA PCa and is associated with various clinicopathological features in AA men with PCa.